95
Participants
Start Date
September 5, 2019
Primary Completion Date
January 8, 2024
Study Completion Date
March 3, 2027
elzovantinib (TPX-0022)
Oral elzovantinib (TPX-0022) capsules
Local Institution - 2112, Fairfax
Local Institution - 4104, Madrid
Local Institution - 4103, Madrid
Local Institution - 4101, Madrid
Local Institution - 4102, Pamplona
Local Institution - 4202, La Tronche
Local Institution - 2104, Toledo
Local Institution - 2106, Ann Arbor
Local Institution - 2113, Detroit
Local Institution - 2111, Chicago
Local Institution - 2103, St Louis
Local Institution - 4201, Lyon
Local Institution - 2105, Denver
Local Institution - 2102, La Jolla
Local Institution - 2108, Orange
Local Institution - 4203, Saint-Mandé
Local Institution - 4204, Villejuif
Local Institution - 2107, Boston
Local Institution - 2109, Boston
Local Institution - 2101, Houston
Local Institution - 6304, Seoul
Local Institution - 6301, Seoul
Local Institution - 6303, Seoul
Local Institution - 6302, Seoul
Turning Point Therapeutics, Inc.
INDUSTRY